Longevity Report · Week of August 29, 2026
Senescence's dark side, protein ceilings, NAD biomarkers, resistance-training doses, and CAC blind spots
- Senescent Cells Turn Traitor: New Preclinical Data Link Them to Cancer Relapse and Cardiac ThrombosisThere is a contradiction buried in two of these papers, and it is worth sitting with before anything else.
- The Protein Ceiling: 100g Beats 25g for Muscle Synthesis by Only 20–30%Thirteen grams of new muscle protein from 100 grams of milk protein. Four and a half grams from 25 grams. That is the number the viral posts led with, and on its face it looks like a rout: nearly three times the muscle b…
- NAD's Wrong Yardstick: Trial Shows Intracellular NAD Rises Without Plasma ChangeThe number is p = 5.48e−14. That is how confidently the RENEWAL-NAD+ trial can say that its intracellular NAD signal is real: a 53% rise in whole-blood icNAD versus placebo at Day 6, with an effect size of Hedges' g = 3.…
- Resistance Training's Sweet Spot: Converging Cohorts Point to Roughly Two Hours a WeekArticle — "Resistance Training's Sweet Spot: Converging Cohorts Point to Roughly Two Hours a Week": Article — "Resistance Training's Sweet Spot: Converging Cohorts Point to Roughly Two Hours a Week": Two sources in your …
- Zero Calcium, False Comfort: Why a CAC Score of Zero Can Still Hide Heart RiskZero Calcium, False Comfort: Why a CAC Score of Zero Can Still Hide Heart Risk
Threads we are following
- Whether any senolytic or senostatic reaches a human trial defining the safe timing window for clearing versus quieting senescent cells
- Will a multi-week lean-mass trial (not acute MPS) confirm that spread ~25g feedings match a single 100g bolus?
- Will Bryleos/BioNADRx run a prospective, adequately powered functional trial to test whether intracellular NAD delivery translates into healthspan benefit?
- Whether any randomized trial will ever test a specific weekly strength-training dose against longevity outcomes
- Whether prevention guidelines will formally incorporate NMR lipoprotein-particle testing to complement CAC in younger patients and women
One issue a week. Free.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.